|
US2017273982A1
|
|
Pulse dosing regimen and methods of treatment
|
|
WO2017164887A1
|
|
Pulse dosing regimen and methods for treatment
|
|
WO2014126954A1
|
|
Regioselective synthesis of substituted pyrimidines
|
|
WO2013152342A1
|
|
Anti-cancer mtor inhibitor and anti-androgen combination
|
|
WO2013152252A1
|
|
Combination anti-cancer therapy
|
|
WO2013078138A1
|
|
Proton nmr spectroscopy for biochemical screening
|
|
EP2776444A1
|
|
Dihydropteridinones
|
|
WO2012158658A1
|
|
Fused bicyclic kinase inhibitors
|
|
WO2012149014A1
|
|
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
|
WO2012129145A1
|
|
Nsclc combination therapy
|
|
WO2012074951A1
|
|
Macrocyclic kinase inhibitors
|
|
BR112013002321A2
|
|
process for the preparation of compound osi-906
|
|
EP2585466A1
|
|
Polymorphs of osi-906
|
|
WO2011143646A1
|
|
Fused bicyclic kinase inhibitors
|
|
TW201141863A
|
|
Fused bicyclic kinase inhibitors
|
|
EP2544672A1
|
|
Combination anti-cancer therapy
|
|
AU2011223655A1
|
|
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
WO2011109593A1
|
|
Substituted-5-aminopyrrolo/pyrazolopyridines
|
|
AU2011223643A1
|
|
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
US2012046267A1
|
|
7-aminofuropyridine derivatives
|
